Journal of Clinical Oncology, Vol 3, 311-315, Copyright © 1985 by American Society of Clinical Oncology
Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance
DR Bell, JH Gerlach, N Kartner, RN Buick and V Ling
A multidrug resistance phenotype is frequently observed in animal and human
cell lines selected for in vitro resistance to a single chemotherapeutic
agent. Overexpression of a highly conserved cell- surface glycoprotein
(P-glycoprotein) is consistently associated with this phenotype in these
mutant lines. A monoclonal antibody against P- glycoprotein was used to
examine tumor samples from five patients with advanced ovarian cancer for
evidence of P-glycoprotein overexpression. High levels of P-glycoprotein
were detected in samples from two patients suggesting that a multidrug
resistance mutation may also occur in ovarian cancer. This finding has
broad implications for the understanding of nonresponse to chemotherapy in
a variety of human neoplasms, and may provide a rational explanation for
failure of chemotherapy in treatment of advanced ovarian cancer.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. B. Kaye
Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go From Here?
J. Clin. Oncol.,
June 1, 2008;
26(16):
2616 - 2618.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Albertus and R. Laine
Enhanced xenobiotic transporter expression in normal teleost hepatocytes: response to environmental and chemotherapeutic toxins
J. Exp. Biol.,
January 1, 2001;
204(2):
217 - 227.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. J. Lee, S. L. George, M. Caligiuri, T. P. Szatrowski, B. L. Powell, S. Lemke, R. K. Dodge, R. Smith, M. Baer, and C. A. Schiffer
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
J. Clin. Oncol.,
September 1, 1999;
17(9):
2831 - 2831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nakayama, M. Wada, T. Harada, J. Nagayama, H. Kusaba, K. Ohshima, M. Kozuru, H. Komatsu, R. Ueda, and M. Kuwano
Hypomethylation Status of CpG Sites at the Promoter Region and Overexpression of the Human MDR1 Gene in Acute Myeloid Leukemias
Blood,
December 1, 1998;
92(11):
4296 - 4307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lau, S. Nightingale, G. P. Taylor, T. W. Gant, and A. J. Cann
Enhanced MDR1 Gene Expression in Human T-Cell Leukemia Virus-I-Infected Patients Offers New Prospects for Therapy
Blood,
April 1, 1998;
91(7):
2467 - 2474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kelley, Z. P. Pavelic, M. Gapany, P. Stambrook, L. Pavelic, S. Gapany, and J. L. Gluckman
Detection of P-Glycoprotein in Squamous Cell Carcinomas of the Head and Neck
Arch Otolaryngol Head Neck Surg,
April 1, 1993;
119(4):
411 - 414.
[Abstract]
[PDF]
|
|
|
|
|
|
|
U Landegren, R Kaiser, C. Caskey, and L Hood
DNA diagnostics--molecular techniques and automation
Science,
October 14, 1988;
242(4876):
229 - 237.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Kramer, J Zakher, and G Kim
Role of the glutathione redox cycle in acquired and de novo multidrug resistance
Science,
August 5, 1988;
241(4866):
694 - 697.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. M. MUGGIA, M. J. PICCART, and J. L. SPEYER
Ovarian Cancer: New Therapeutic Concepts, Renewed Optimism
Ann Intern Med,
November 1, 1985;
103(5):
795 - 797.
[Abstract]
[PDF]
|
|
|
|
